This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Sirtris Pharmaceuticals, Inc., Synta Pharmaceuticals Corporation, R.p.scherer Technologies, Inc.. Active years: 2010-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 14 
2 out of 162 
1 out of 126 
Years Active: 2010-2017
Title: The Innovative Contributions of Walter Lunsmann
Introduction
Walter Lunsmann is a notable inventor based in Harvard, MA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of five patents to his name, Lunsmann has made strides in developing formulations that enhance drug delivery and efficacy.
Latest Patents
Among his latest patents, Lunsmann has developed formulations containing substituted imidazole derivatives. These formulations are designed to be in solid fast-dispersing dosage forms suitable for pre-gastric absorption. Another notable patent is the bis(thio-hydrazide amide) formulation, which comprises a compound that can be reconstituted in water in less than ten minutes. These innovations reflect his commitment to improving pharmaceutical formulations for better patient outcomes.
Career Highlights
Lunsmann has worked with prominent companies in the pharmaceutical industry, including Sirtris Pharmaceuticals, Inc. and Synta Pharmaceuticals Corporation. His experience in these organizations has allowed him to contribute to various projects that focus on drug development and formulation.
Collaborations
Some of his notable coworkers include Jean E Bemis and Jeremy S Disch. Their collaborative efforts have likely played a role in advancing the innovative work that Lunsmann is known for.
Conclusion
Walter Lunsmann's contributions to pharmaceutical innovations through his patents and collaborations highlight his role as a significant inventor in the industry. His work continues to influence the development of effective drug formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile